Neurovascular Permeability Score (NVPS): Composite Plasma + Imaging Biomarker P…

Mechanistic description

A LASSO-optimized composite score integrating plasma GFAP, S100B, NFL, soluble PDGFR-β, and claudin-5 fragments to achieve AUC >0.90 for pre-symptomatic AD/PD, outperforming single-marker approaches including amyloid PET.

Evidence for (5)

Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease.

PMID:39249107 2024 J Neurol
Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics.

PMID:38253262 2024 Clin Chem Lab Med
Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.

PMID:36878332 2023 Brain Behav Immun
GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis.

PMID:37174709 2023 Cells
Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.

PMID:35852967 2023 Alzheimers Dement

Evidence against (2)

Blood GFAP changes occur across Alzheimer biomarker and all-cause dementia contexts, so GFAP alone is not specific for BBB dysfunction or astrocyte end-foot retraction.

PMID:39068543 2024 JAMA
Plasma biomarkers associate with both neurodegenerative atrophy and microvascular burden, complicating interpretation of GFAP as a selective neurovascular permeability readout.

PMID:40063856 2025 Neurology

Evidence matrix

5 supporting 2 contradicting

53% posterior support

Supporting

Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease. PMID:39249107 · 2024 · J Neurol
Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics. PMID:38253262 · 2024 · Clin Chem Lab Med
Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies. PMID:36878332 · 2023 · Brain Behav Immun
GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. PMID:37174709 · 2023 · Cells
Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years. PMID:35852967 · 2023 · Alzheimers Dement

Contradicting

Blood GFAP changes occur across Alzheimer biomarker and all-cause dementia contexts, so GFAP alone is not specific for BBB dysfunction or astrocyte end-foot retraction. PMID:39068543 · 2024 · JAMA
Plasma biomarkers associate with both neurodegenerative atrophy and microvascular burden, complicating interpretation of GFAP as a selective neurovascular permeability readout. PMID:40063856 · 2025 · Neurology

Bayesian persona consensus

53% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). Neurovascular Permeability Score (NVPS): Composite Plasma + Imaging Biomarker P…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-e9e0225d

BibTeX

@misc{scidex_hypothesis_he9e0225,
  title        = {Neurovascular Permeability Score (NVPS): Composite Plasma + Imaging Biomarker P…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-e9e0225d},
  note         = {SciDEX artifact hypothesis:h-e9e0225d}
}